<DOC>
	<DOCNO>NCT00087659</DOCNO>
	<brief_summary>This study conduct compare effect investigational drug versus placebo bone loss men prostate cancer receive Androgen Deprivation Therapy ( ADT ) . The study drug placebo administer every three month four treatment one year . In order participate , male patient 18 year old must consecutive veteran participate Veterans Administration Medical Centers .</brief_summary>
	<brief_title>A Prostate Cancer Study Men Undergoing Androgen Deprivation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>Signed informed consent Age &gt; 18 year Histologically confirm diagnosis carcinoma prostate No distant metastases start ADT continuously low PSA ( &lt; 2.0 ) continuous ADT ( stage Tany Nany MO ) . Patients initiate receive ADT LHRH agonist ( without antiandrogen ) intend duration ADT least 12 month time randomization . Patients undergoing bilateral orchiectomy history procedure also eligible . Patient baseline BMD Tscore 2.0 standard deviation lumbar spine ( L2L4 ) total hip eligible Life expectancy least 12 month Zubrod performance status 0 , 1 , 2 Patients receive prior bisphosphonate therapy past 6 month Metabolic bone disease include Paget 's disease hyperparathyroidism Radiographic evidence bone metastases Patients receive prior treatment systemic corticosteroid within past 12 month ( short term corticosteroid therapy , e.g . prevent/treat chemotherapyinduced nausea/vomiting acute illness like asthma exacerbation , acceptable ) Patients prior exposure anabolic steroid growth hormone within past 6 month Current treatment estrogen complementary medicine know contain estrogens Patients clinical radiological evidence exist fracture lumbar spine and/or total hip Patients history fracture lowintensity associate trauma Patients prior treatment osteoporosis Patients previous concomitant malignancy within past 5 year except adequately treat basal squamous cell carcinoma skin , colonic polyp noninvasive malignancy remove Patients nonmalignant condition would confound evaluation primary endpoint , impair tolerance therapy , prevent compliance protocol , include : uncontrolled infection uncontrolled type 2 diabetes mellitus disease influence bone metabolism , Paget 's disease uncontrolled thyroid parathyroid dysfunction cardiovascular , renal , hepatic , pulmonary neurologic/psychiatric disease would prevent prolonged followup History surgery lumbosacral spine , without implantable device , bilateral hip replacement bilateral hip surgery implantation appliance Patients treat systemic investigational drug ( ) /or device ( ) within past 30 day Patients abnormal renal function evidence either serum creatinine great 3 mg/dL calculate creatinine clearance 60 ml/minute less Corrected ( adjust serum albumin ) serum calcium concentration &lt; 8.0 mg/dl ( 2.00 mmol/L ) Subjects , opinion investigator , unlikely cooperate fully study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>ADT , BMD , US63 , H014</keyword>
</DOC>